Key issues of diagnosis and treatment of acquired immunodeficiency syndrome complicated with tuberculosis

doi:10.19983/j.issn.2096-8493.20220156

Abstract

Abstract:

Tuberculosis is a common opportunistic infection and an important factor in disease progression in patients with human immunodeficiency virus (HIV) infection/acquired immunodeficiency syndrome (AIDS), and is also one of the main causes of death in HIV infection/AIDS patients. With the deepening of understanding of the two diseases and the accumulation of relevant clinical research evidence, people pay more and more attention to some problems in the diagnosis and treatment of AIDS combined with tuberculosis.In combination with the consensus of domestic experts on AIDS complicated with tuberculosis in 2022 and clinical practice, the author reviewed several key issues such as the screening direction of this special group, the application of new diagnostic techniques, the efficacy of short-term anti-tuberculosis regimen, the selection and timing of antiviral drugs, the interaction between integrase inhibitors and rifamycin, and the identification and treatment of tuberculosis related immune reconstitution inflammatory response syndrome.

Key words: Acquired immunodeficiency syndrome, Tuberculosis, Diagnosis, Therapeutic uses, Review litera-ture as topic

CLC Number:

R512.91
R52

Huang Wei, Shen Yinzhong. Key issues of diagnosis and treatment of acquired immunodeficiency syndrome complicated with tuberculosis[J]. Journal of Tuberculosis and Lung Disease , 2022, 3(6): 431-436. doi: 10.19983/j.issn.2096-8493.20220156

References 32

[1]	UNAIDS. Global HIV&AIDS Statistics-Fact Sheet[EB/OL]. [2022-07-29]. https://www.unaids.org/en/resources/fact-sheet.
[2]	World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization, 2022.
[3]	Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS, 2009, 4(4): 325-333. doi:10.1097/COH.0b013e32832c7d61. doi: 10.1097/COH.0b013e32832c7d61 URL pmid: 19532072
[4]	中华医学会感染病学分会艾滋病学组, 中华医学会热带病与寄生虫学分会艾滋病学组. HIV合并结核分枝杆菌感染诊治专家共识. 中华临床感染病杂志, 2017, 10(2):81-90. doi:10.3760/cma.j.issn.1674-2397.2017.02.001. doi: 10.3760/cma.j.issn.1674-2397.2017.02.001 URL
[5]	中国性病艾滋病防治协会HIV合并结核病专业委员会. 人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识. 中华传染病杂志, 2022, 40(1):6-19. doi:10.3760/cma.j.cn311365-20211105-00387. doi: 10.3760/cma.j.cn311365-20211105-00387 URL
[6]	Gupta RK, Lucas SB, Fielding KL, et al. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS, 2015, 29(15): 1987-2002. doi:10.1097/QAD.0000000000000802. doi: 10.1097/QAD.0000000000000802 URL pmid: 26266773
[7]	Kraef C, Bentzon A, Panteleev A, et al. Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality-a multicentre prospective cohort study. BMC Infect Dis, 2021, 21(1):1038. doi:10.1186/s12879-021-06745-w. doi: 10.1186/s12879-021-06745-w URL pmid: 34615474
[8]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 2: Screening-Systematic screening for tuberculosis disease. Geneva:World Health Organization, 2021.
[9]	World Health Organization. Global tuberculosis report 2022, Geneva: World Health Organization, 2020.
[10]	Hamada Y, Lujan J, Schenkel K, et al. Sensitivity and specificity of WHO’s recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis. Lancet HIV, 2018, 5(9): e515-e523. doi:10.1016/S2352-3018(18)30137-1. doi: 10.1016/S2352-3018(18)30137-1 URL
[11]	Hanifa Y, Fielding KL, Chihota VN, et al. A clinical scoring system to prioritise investigation for tuberculosis among adults attending HIV clinics in South Africa. PLoS One, 2017, 12(8): e0181519. doi:10.1371/journal.pone.0181519. doi: 10.1371/journal.pone.0181519 URL
[12]	Ouyang J, Yuan J, Chen Y, et al. The development and validation of a diagnostic scoring system to differentiate pulmonary tuberculosis from non-tuberculosis pulmonary infections in HIV-infected patients with severe immune suppression. BMC Infect Dis, 2021, 21(1): 863. doi:10.1186/s12879-021-06552-3. doi: 10.1186/s12879-021-06552-3 URL pmid: 34425768
[13]	Shapiro AE, Hong T, Govere S, et al. C-reactive protein as a screening test for HIV-associated pulmonary tuberculosis prior to antiretroviral therapy in South Africa. AIDS, 2018, 32(13): 1811-1820. doi:10.1097/QAD.0000000000001902. doi: 10.1097/QAD.0000000000001902 URL pmid: 29847333
[14]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis-rapid diagnostics for tuberculosis detection, 2021 update. Geneva: World Health Organi-zation, 2021.
[15]	Centers for Disease Control and Prevention. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep, 2009, 58(1): 7-10.
[16]	Di Tanna GL, Khaki AR, Theron G, et al. Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. Lancet Glob Health, 2019, 7(2): e191-e199. doi:10.1016/S2214-109X(18)30458-3. doi: 10.1016/S2214-109X(18)30458-3 URL
[17]	Esmail A, Tomasicchio M, Meldau R, et al. Comparison of Xpert MTB/RIF (G4) and Xpert Ultra, including trace readouts, for the diagnosis of pulmonary tuberculosis in a TB and HIV endemic setting. Int J Infect Dis, 2020, 95:246-252. doi:10.1016/j.ijid.2020.03.025. doi: S1201-9712(20)30144-2 URL pmid: 32247825
[18]	Zhang P, Liu H, Wang H, et al. Performance of Xpert MTB/RIF Ultra for the Diagnosis of Pulmonary Tuberculosis Using Bronchoalveolar Lavage Samples in People Living with HIV/AIDS (PLWHA) in China: A Prospective Study. HIV AIDS (Auckl), 2021, 13:905-916. doi:10.2147/HIV.S319117. doi: 10.2147/HIV.S319117 URL
[19]	Broger T, Sossen B, du Toit E, et al. Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. Lancet Infect Dis, 2019, 19(8):852-861. doi:10.1016/S1473-3099(19)30001-5. doi: S1473-3099(19)30001-5 URL pmid: 31155318
[20]	Miguez-Burbano MJ, Flores M, Ashkin D, et al. Non-tuberculous mycobacteria disease as a cause of hospitalization in HIV-infected subjects. Int J Infect Dis, 2006, 10(1):47-55. doi:10.1016/j.ijid.2004.11.005. doi: 10.1016/j.ijid.2004.11.005 URL pmid: 16290202
[21]	Panel on Opportunistic Infection in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV[EB/OL]. [2022-06-09]. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/mycobacterium-0?view=full.
[22]	Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med, 2021, 384(18): 1705-1718. doi:10.1056/NEJMoa2033400. doi: 10.1056/NEJMoa2033400 URL
[23]	World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization, 2021.
[24]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-susceptible tuberculosis treatment. Geneva: World Health Organization, 2022.
[25]	World Health Organization. Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring: March 2021.Geneva: World Health Organization, 2021.
[26]	Dooley KE, Kaplan R, Mwelase N, et al. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial. Clin Infect Dis, 2020, 70(4): 549-556. doi:10.1093/cid/ciz256. doi: 10.1093/cid/ciz256 URL pmid: 30918967
[27]	Le X, Guo X, Sun J, et al. Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex. Int J Infect Dis, 2022, 116: 147-150. doi:10.1016/j.ijid.2022.01.001. doi: 10.1016/j.ijid.2022.01.001 URL pmid: 34999246
[28]	Grinsztejn B, De Castro N, Arnold V, et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis, 2014, 14(6): 459-467. doi:10.1016/S1473-3099(14)70711-X. doi: 10.1016/S1473-3099(14)70711-X URL pmid: 24726095
[29]	De Castro N, Marcy O, Chazallon C, et al. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial. Lancet Infect Dis, 2021, 21(6): 813-822. doi:10.1016/S1473-3099(20)30869-0. doi: 10.1016/S1473-3099(20)30869-0 URL
[30]	Kendall MA, Lalloo U, Fletcher CV, et al. Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir+Rifampin Versus Lopinavir/Ritonavir+Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection. Clin Infect Dis, 2021, 73(4): 706-715. doi:10.1093/cid/ciab097. doi: 10.1093/cid/ciab097 URL
[31]	Namale PE, Abdullahi LH, Fine S, et al. Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis. Future Microbiol, 2015, 10(6): 1077-1099. doi:10.2217/fmb.15.9. doi: 10.2217/fmb.15.9 URL pmid: 26059627
[32]	Meintjes G, Stek C, Blumenthal L, et al. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. N Engl J Med, 2018, 379(20): 1915-1925. doi:10.1056/NEJMoa1800762. doi: 10.1056/NEJMoa1800762 URL